Commonalities between cardiovascular, renal and metabolic (CaReMe) diseases with clinical overlap between these diseases and their associated complications are increasingly recognized. AstraZeneca conducts a European study program in 10 countries according to a common protocol to address specific unanswered questions on the epidemiology of CaReMe disorders and the impact of these on healthcare utilization, using the French claims database (SNDS) for the French part of the program. The French cohort will include all adult type 2 diabetes (T2D) patients in 2014 with a follow-up of 5 years and having 4-year history period before the index date (01/01/2014) in the database. The cardiovascular and renal disease-free T2D population will include all T2D patients without angina, unstable angina, atrial fibrillation, myocardial infarction (MI), heart failure (HF), coronary revascularisation, stroke, transient ischemic attack, peripheral artery disease (PAD), peripheral artery revascularisation, chronic kidney disease (CKD) or dispensing of nitrates within the 4-year period before the index date. Several co-morbid T2D populations will be defined as cardiorenal syndrome (HF and CKD) population, HF population, CKD population, stroke population, MI population and PAD population. It is expected for the study approximately 3 million of T2D population in 2015. The events of interest (cardiorenal disease HF or CKD, HF, CKD, PAD, MI, stroke, and all-cause death) during the study period will be described in terms of crude incidence rate (person-year), cumulative incidence/probability (in %, Kaplan-Meier estimator or Cumulative Incidence Function), and risk comparison for each event between disease-free and co-morbid populations (Cox proportional hazards model or Fine and Grey Model). Specific cost (all payer perspective) of HF, CKD, cardiorenal diseases (HF or CKD), PAD, MI, or stroke will be estimated during the follow-up in T2D patients free from cardiovascular and renal diseases.